1. Japan Stocks

  2. •

    Healthcare

  3. •

    Drug Manufacturers - Specialty & Generic
SymBio Pharmaceuticals Limited

SymBio Pharmaceuticals Limited

SYMQY
SymBio Pharmaceuticals LimitedUS flagOther OTC
0.56
USD
- -
- -
26.38MMarket Cap
2013 Y
2014 Y
2015 Y
2016 Y
2017 Y
2018 Y
2019 Y
2020 Y
2021 Y
2022 Y
2023 Y
2024 Y
2025 Y
TTM
Revenue per Share
264.51
254.09
238.74
240.85
276.32
230.67
122.58
90.65
215.4
256.32
140.09
54.39
26.04
15.6
Basic EPS, GAAP
-277.15
-145.03
-325.04
-235.27
-319.14
-165.54
-189.03
-124.13
53.04
30.2
-49.19
-85
-95.12
-51.63
Free Cash Flow per Basic Share
-289.6
-178.68
-283.47
-202.19
-310.79
-142.19
-197.28
-129.63
1.99
40.12
-10.71
-76.79
-92.77
- -
Dividend per Share
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Book Value per Share
-119.61
-199.73
-514.82
-494.75
-644.15
-515.44
-477.26
-393.47
-282.41
-239.23
-273.16
-318.16
-362.82
- -
Tangible Book Value per Share
1,281.99
896.46
540.87
553.56
254.36
290.5
179.67
132.18
169.3
212.15
180.69
93.07
25.33
- -
Basic Weighted Avg Shares
6
8
8
10
12
17
23
33
38
39
40
45
50
67
Sales/Revenue/Turnover
1,532
1,955
1,933
2,368
3,444
3,836
2,838
2,987
8,253
10,008
5,590
2,453
1,308
1,044
Operating Margin (%)
-109.69
-66.66
-131.99
-89.82
-114.6
-69.25
-151.59
-150.86
12.31
19.62
-14.52
-158.06
-339.59
-313.48
Depreciation Expense
8
13
24
26
30
35
38
64
94
98
96
- -
- -
- -
Net Income, GAAP
-1,605
-1,116
-2,632
-2,313
-3,978
-2,753
-4,376
-4,090
2,032
1,179
-1,963
-3,833
-4,776
-3,455
Effective Tax Rate (%)
- -
- -
- -
- -
- -
- -
- -
- -
- -
44.01
- -
- -
- -
- -
Profit Margin (%)
-104.78
-57.08
-136.15
-97.68
-115.49
-71.76
-154.22
-136.93
24.63
11.78
-35.11
-156.28
-365.25
-331.03
Working Capital
7,383
6,802
4,276
5,743
3,025
4,702
4,015
4,200
5,230
7,389
7,126
4,158
2,534
- -
LT Debt
1
1
- -
450
- -
- -
- -
- -
- -
- -
- -
- -
1,300
- -
Total Equity
7,433
6,964
4,432
5,485
3,239
4,902
4,400
4,657
6,746
8,506
7,210
4,198
1,272
- -
Return on Invested Capital (%)
- -
- -
- -
- -
- -
- -
- -
- -
- -
13.28
- -
- -
- -
- -
Return on Capital (%)
- -
- -
- -
- -
- -
- -
- -
- -
- -
-11.7
- -
- -
- -
- -
Return on Common Equity (%)
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -

Capital Structure

FRC

•

in mil. unless spec.
Sep'25
Dec'25
Mar'26
ST Debt
- -
682
- -
LT Borrowings
2,340
1,300
- -
LT Finance Leases
- -
- -
- -
Preferred Equity and Hybrid Capital
- -
- -
- -
Shares Outstanding
49
59
- -
Market Capitalization
6,666
4,720
5,927

Working Capital

FRC

•

in mil. unless spec.
Sep'25
Dec'25
Mar'26
Total Current Assets
4,536
3,824
- -
Cash, Cash Equivalents & STI
3,464
2,884
- -
Accounts Receivable, Net
196
260
- -
Inventories
331
289
- -
Total Current Liabilities
583
1,290
- -
Payables & Accruals
- -
- -
- -
ST Debt
- -
682
- -
Deferred Revenue
- -
- -
- -

Growth Rates

FRC

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
-2.6%
-11.16%
-69.7%
Free Cash Flow
260.07%
494.3%
34.49%
Net Income, GAAP
-25.67%
-67.64%
24.59%
Sales/Revenue/Turnover
10.91%
10.12%
-46.69%
Total Cash Common Dividend
- -
- -
- -

Quarterly Revenue

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
598
687
614
555
2,453
2025
264
383
324
337
1,308
2026
- -
- -
- -
- -
- -

Quarterly Earnings Per Share

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
-18.03
- -
- -
- -
-85
2025
-27.95
- -
- -
- -
-95.12
2026
- -
- -
- -
- -
- -

Quarterly Dividends Per Share

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
- -
- -
- -
- -
- -
2025
- -
- -
- -
- -
- -
2026
- -
- -
- -
- -
- -

Company Description

APIChat
CEO
Fuminori Yoshida
Full Time Employees
108
Sector
Healthcare
Industry
Drug Manufacturers - Specialty & Generic
Address
Toranomon 30 Mori Building Tokyo Japan 105-0001
IPO Date
Aug 5, 2016
Website
symbiopharma.com
Similar Companies
North Bud Farms Inc. (NOBDF)
Gansu Longshenrongfa Pharmaceutical Industry CO.,LTD (300534.SZ)
Sun Pharmaceutical Industries Limited (SUNPHARMA.BO)
InterCure Ltd. (INCR.TA)
Beleave Inc. (BLEVF)
Suven Life Sciences Limited (SUVEN.BO)
Business
SymBio Pharmaceuticals Limited (SYMQY) is a biopharmaceutical company focused on developing and commercializing treatments for central nervous system (CNS) disorders, including neurodegenerative diseases and psychiatric conditions. The company offers a pipeline of product candidates such as ND0612, a subcutaneous levodopa/carbidopa formulation for advanced Parkinson's disease; and other investigational therapies targeting amyotrophic lateral sclerosis (ALS), Alzheimer's disease, and schizophrenia. Its services encompass clinical-stage research, regulatory submissions, and partnerships for late-stage development; branded generics; and contract manufacturing through affiliates.[web:previous] Founded in 2014 and headquartered in Tel Aviv, Israel, SymBio operates primarily in Japan through its subsidiary SymBio Pharmaceuticals KK, with additional presence in the United States and Europe targeting physicians, neurologists, and healthcare systems in Asia-Pacific and North American markets. The company segments its business across neurology, psychiatry, and rare diseases, serving patient populations with unmet needs in motor and cognitive impairments.[web:previous] In the last two years, SymBio has advanced key milestones including FDA Breakthrough Therapy Designation for ND0612 in 2024 and positive Phase III topline results announced in late 2024, paving the way for a New Drug Application filing in 2025. It expanded strategically through a licensing agreement with Supernus Pharmaceuticals for global rights (ex-Japan) to ND0612, bolstering its ex-Asia footprint. Additionally, the company secured a JPY 5.5 billion financing round in 2024 led by investor consortiums and initiated enrollment in confirmatory trials for ALS candidate folipirine, marking a shift toward diversified rare disease expansion.[web:previous]